Global Hepatitis C Drugs Market 2019-2023 | Evolving Opportunities with AbbVie and Gilead | Technavio

LONDON–(BUSINESS WIRE)–#Biotechnology–Technavio has been monitoring the global hepatitis C drugs market and the market is poised to post a decremental growth of USD -5.72 billion during 2019-2023. Request Free Sample Pages

Read the 125-page research report with TOC on “Hepatitis C Drugs Market Analysis Report by Product (Combination therapy and Monotherapy), by Type (Acute hepatitis C and Chronic hepatitis C), by Geography (APAC, EMEA, and Americas), and Segment Forecasts, 2019 – 2023”.

https://www.technavio.com/report/global-hepatitis-c-drugs-market-industry-analysis

The high prevalence of hepatitis C and increasing number of voluntary licensing agreements are anticipated to boost the growth of the market.

Individuals addicted to opioids and patients on parenteral therapy are highly susceptible to hepatitis C as it is a blood-borne infection. Lack of awareness about hepatitis C disease in developing countries is leading to an increase in the death rate. In developed countries, almost half of the patients with hepatitis C remain undiagnosed. In addition, the prevalence of hepatitis C is higher among males than females. All these factors are driving the need for better diagnosis of hepatitis C and the prescription of hepatitis C drugs by physicians. Thus, the high prevalence of hepatitis C is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Hepatitis C Drugs Market Companies:

AbbVie

AbbVie is headquartered in the US and operates the business under the Pharmaceutical products segment. The company offers MAVYRET, which is indicated for the treatment of adult patients with chronic hepatitis C.

Bristol-Myers Squibb

Bristol-Myers Squibb is headquartered in the US and offers products through the Biopharmaceuticals business unit. The company offers DAKLINZA, which is indicated for the treatment of patients with chronic HCV genotype 1 or genotype 3 infection.

F. Hoffmann-La Roche

F. Hoffmann-La Roche is headquartered in Switzerland and operates under various business segments, namely Pharmaceuticals and Diagnostics. The company offers COPEGUS, which is indicated in combination with PEGASYS for the treatment of patients with chronic HCV infection.

Gilead

Gilead is headquartered in the US and offers products through the Biopharmaceuticals business segment. The company offers HARVONI, EPCLUSA, and SOVALDI.

Merck

Merck is headquartered in the US and offers products through the following business segments: Pharmaceutical and Other segments. The company offers ZEPATIER, which is indicated for the treatment of chronic hepatitis C genotype 1 or 4 infection in adults.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Hepatitis C Drugs Product Outlook (Revenue, USD Million, 2019 – 2023)

• Combination therapy
• Monotherapy

Hepatitis C Drugs Regional Outlook (Revenue, USD Million, 2019 – 2023)

• Americas
• APAC
• EMEA

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Alcoholic Hepatitis Treatment Market – Global Alcoholic Hepatitis Treatment Market by type (corticosteroids, xanthine derivatives, and others) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]
Website: https://www.technavio.com